LENSAR, Inc.
LNSRHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeLENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically. The company carries a $70.7M market cap, placing it firmly in the micro-cap category. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.
Market Cap
$70.7M
Beta
0.87
P/E (TTM)
—
P/E (Fwd)
-8.11
EPS (TTM)
$-0.55
EPS (Fwd)
$-0.71
ROE
362.6%
ROA
-22.6%
Cash
$13.5M
Total Debt
$2.6M
Free CF
-$22.7M
52W Change
-55.9%
Annual Financials
Cash vs Debt
Where LNSR stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, LNSR finished 32.63% below its 150-day moving average ($8.55) and 37.73% below its 200-day moving average ($9.25). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LNSR overbought or oversold?
At the July 15, 2026 close, LNSR's RSI(14) was 50.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $13.5M in cash and $2.6M in debt, LNSR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$22.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 362.6% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $35.4M (2022) to $58.4M (2025), reflecting a 65% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing LNSR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.